Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.81 |
| ▸ | ESRRA | P11474 | 1/20 | 0.70 |
| ▸ | FFAR1 | O14842 | 12/20 | 0.62 |
| ▸ | PPARA | Q07869 | 6/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7248263 | 0.99 | PPARG (0.80) | PPARGESRRAFFAR1PPARAHRH3 | |
| SCHEMBL15483700 | 0.90 | PPARG (0.83) | PPARGESRRAFFAR1PPARAHRH3 | |
| Rivoglitazone SCHEMBL5319250 | 0.90 | PPARG (1.00) | PPARGESRRAFFAR1PPARA | |
| Rivoglitazone SCHEMBL143498 | 0.90 | PPARG (1.00) | PPARGESRRAFFAR1PPARA | |
| SCHEMBL13875535 | 0.90 | PPARG (0.83) | PPARGESRRAFFAR1PPARAHRH3 | |
| Hydrochloric Acid SCHEMBL6701457 | 0.90 | PPARG (0.83) | PPARGESRRAFFAR1PPARAHRH3 | |
| Rivoglitazone SCHEMBL2906120 | 0.90 | PPARG (1.00) | PPARGESRRAFFAR1PPARA | |
| Rivoglitazone SCHEMBL6064788 | 0.89 | PPARG (0.98) | PPARGESRRAFFAR1PPARA | |
| Rivoglitazone SCHEMBL1592290 | 0.89 | PPARG (0.98) | PPARGESRRAFFAR1PPARA | |
| SCHEMBL7243625 | 0.88 | PPARG (0.80) | PPARGESRRAFFAR1PPARAHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6569877-B2 | Benzimidazolyl phenyl anticancer agents | SANKYO COMPANY, LIMITED (JP) | 2003-05-27 | — | — | US | claimed |
| US-20020137776-A1 | Therapeutic and prophylactic agents for neoplasms | SANKYO COMPANY, LIMITED (JP) | 2002-09-26 | — | — | US | claimed |
| EP-1197211-A1 | PREVENTIVE AND THERAPEUTIC AGENTS FOR CANCER | Sankyo Company, Limited (JP) | 2002-04-17 | — | — | EP | claimed |
| US-6569877-B2 | Benzimidazolyl phenyl anticancer agents | SANKYO COMPANY, LIMITED (JP) | 2003-05-27 | — | — | US | disclosed |
| US-20020137776-A1 | Therapeutic and prophylactic agents for neoplasms | SANKYO COMPANY, LIMITED (JP) | 2002-09-26 | — | — | US | disclosed |
| EP-1197211-A1 | PREVENTIVE AND THERAPEUTIC AGENTS FOR CANCER | Sankyo Company, Limited (JP) | 2002-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137776-A1 | Therapeutic and prophylactic agents for neoplasms | VHL, TP53, BRCA1 | PPARG 1300/4885ESRRA 4106/4885FFAR1 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.